Brokerages Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Target Price at $50.57

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIOGet Rating) have been assigned an average recommendation of “Hold” from the eight research firms that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $50.57.

A number of research firms have issued reports on AGIO. SVB Leerink boosted their price objective on shares of Agios Pharmaceuticals to $33.00 and gave the company a “market perform” rating in a report on Tuesday, May 17th. The Goldman Sachs Group cut their price target on shares of Agios Pharmaceuticals from $20.00 to $16.00 and set a “sell” rating for the company in a report on Tuesday, May 24th. Finally, StockNews.com assumed coverage on shares of Agios Pharmaceuticals in a report on Thursday, March 31st. They set a “sell” rating for the company.

NASDAQ AGIO opened at $23.36 on Tuesday. The company has a market capitalization of $1.28 billion, a P/E ratio of -3.62 and a beta of 1.34. Agios Pharmaceuticals has a 12-month low of $16.75 and a 12-month high of $58.61. The firm has a 50-day moving average price of $20.74 and a two-hundred day moving average price of $27.07.

Agios Pharmaceuticals (NASDAQ:AGIOGet Rating) last posted its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.85) by $0.11. The business had revenue of $0.83 million during the quarter, compared to the consensus estimate of $2.71 million. During the same period in the prior year, the firm earned ($1.31) EPS. As a group, research analysts forecast that Agios Pharmaceuticals will post -7.02 earnings per share for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP increased its position in Agios Pharmaceuticals by 34.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 725,401 shares of the biopharmaceutical company’s stock worth $23,845,000 after purchasing an additional 184,903 shares in the last quarter. State Street Corp increased its position in Agios Pharmaceuticals by 25.1% during the 4th quarter. State Street Corp now owns 2,992,882 shares of the biopharmaceutical company’s stock worth $98,376,000 after purchasing an additional 599,992 shares in the last quarter. Royal Bank of Canada increased its position in Agios Pharmaceuticals by 24.8% during the 3rd quarter. Royal Bank of Canada now owns 30,532 shares of the biopharmaceutical company’s stock worth $1,410,000 after purchasing an additional 6,066 shares in the last quarter. Squarepoint Ops LLC acquired a new position in Agios Pharmaceuticals during the 4th quarter worth approximately $1,401,000. Finally, Voloridge Investment Management LLC acquired a new position in Agios Pharmaceuticals during the 3rd quarter worth approximately $805,000.

Agios Pharmaceuticals Company Profile (Get Rating)

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications.

Read More

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.